Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Temasek-led investor group in $250 million vaccine bet on Germany's BioNTech

share with twitter share with LinkedIn share with facebook
06/29/2020 | 10:52am EDT
FILE PHOTO: The headquarters of biopharmaceutical company BioNTech are seen in Mainz

By Ludwig Burger

Singapore's state investor Temasek and other investors are injecting $250 million into German biotech company BioNTech, which is developing an experimental vaccine against the coronavirus with pharmaceutical giant Pfizer.

The investment, which BioNTech said was via a private placement, reflects heightened investor interest in the race to develop an agent that will stop the pandemic and sent shares in biotech firms such as Moderna and Novavax soaring this year.

U.S.-listed shares in the German company jumped almost 15% to their highest since March 19 on the news. They have surged more than 80% so far this year against the Nasdaq biotech index's gain of 12%.

BioNTech, which went public on Nasdaq in October last year, said the investors would purchase about $139 million in ordinary shares and $112 million in 4-year mandatory convertible notes.

It has said it expects first clinical data on its COVID-19 vaccine development programme known as BNT162 this month or in July.

The transaction would increase the number of BioNTech shares outstanding by 2.6 million from 226.8 million shares as per end of March, resulting in a combined stake of 1.1% for the investor group once all notes are converted.

BioNTech, which is also working on personalised cancer vaccines, would not say how much of the total is attributed to Temasek. Temasek would also not comment.

The investment adds to Temasek's healthcare assets that include Singapore biotech firm and COVID-19 treatment developer Tychan, British biotech firm Orchard Therapeutics and Irish drug delivery firm Aerogen.

Life sciences and agribusiness made up 7% of Temasek's holdings in the year to March 2019, up from 3% in the year to 2015.

BioNTech and Pfizer launched testing programmes involving humans in April and May.

Domestic rival vaccine developer CureVac, in which the German government is taking a 23% stake, is planning an initial public offering in the United States next month. U.S. peer Translate Bio has attracted France's Sanofi as an investor in a deal worth as much as $2 billion.

BioNTech, which awarded the rights to BNT162 in China to Shanghai Fosun under a March collaboration deal, is competing with CureVac as well as U.S. biotech firms Moderna and Translate Bio in the race to develop messenger-RNA vaccines.

(Additional reporting by Anshuman Daga in Singapore and Thyagaraju Adinarayan in London; editing by Thomas Seythal and Emelia Sithole-Matarise)

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -2.57% 67.56 Delayed Quote.99.41%
MODERNA, INC. 0.80% 61.58 Delayed Quote.214.83%
NASDAQ COMP. 1.44% 10492.500132 Delayed Quote.15.28%
NOVAVAX, INC. -5.99% 98.3 Delayed Quote.2,369.85%
PFIZER LIMITED -0.54% 4088.45 End-of-day quote.-3.21%
PFIZER, INC. -0.82% 33.75 Delayed Quote.-13.86%
SANOFI SA 0.27% 90.77 Real-time Quote.1.05%
SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD. 0.03% 35.54 End-of-day quote.33.61%
SHANGHAI STOCK EXCHANGE B SHARES INDEX 0.88% 240.956 Real-time Quote.-6.18%
TRANSLATE BIO, INC. 0.34% 17.6 Delayed Quote.116.22%
share with twitter share with LinkedIn share with facebook
Latest news on MODERNA, INC.
07/08MODERNA : Completes Enrollment of Phase 2 Study of its mRNA Vaccine Against COVI..
07/07U.S. Commits $2 Billion for Covid-19 Vaccine, Drug Supplies -- Update
07/07U.S. Commits $2 Billion for Covid-19 Vaccine, Drug Supplies
07/06China's Sinovac starts late stage trials for its COVID-19 vaccine
07/05Coronavirus Is No Cure for Health-Care Stocks
07/05Correction to Poor Performance of Health-Care Stocks Article
07/05Britain nears $625 million Sanofi/GSK COVID-19 vaccine deal - report
07/05Coronavirus Is No Cure for Health-Care Stocks
07/03INOVIO PHARMACEUTICALS : Wall Street shifts bets to big pharma as COVID-19 vacci..
07/02How Moderna executives are cashing in on COVID-19 vaccine stock speculation
More news
Financials (USD)
Sales 2020 109 M - -
Net income 2020 -508 M - -
Net cash 2020 1 752 M - -
P/E ratio 2020 -44,1x
Yield 2020 -
Capitalization 23 944 M 23 944 M -
EV / Sales 2019
EV / Sales 2020 203x
Nbr of Employees 850
Free-Float 79,7%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 86,31 $
Last Close Price 61,58 $
Spread / Highest target 81,9%
Spread / Average Target 40,2%
Spread / Lowest Target -2,57%
EPS Revisions
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.214.83%23 944
LONZA GROUP48.64%41 432
CELLTRION, INC.72.10%34 546